Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Other: CaffeineOther: Vitamin KBiological: BIIB019 (Daclizumab)
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 133
- Registration Number
- NCT01462318
- Locations
- 🇵🇱
Research Site, Krakow, Poland
Phase 1 Study to Evaluate the PK, Safety, and Tolerability of BG00012 in Chinese, Japanese, and Caucasian Healthy Volunteers
- Conditions
- Healthy
- Interventions
- Drug: BG00012 Dose 2Drug: BG00012 Dose 1
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 71
- Registration Number
- NCT01453426
- Locations
- 🇨🇳
Research Site, Hong Kong, Hong Kong, China
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2014-10-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 106
- Registration Number
- NCT01440101
- Locations
- 🇯🇵
Research Site, Yokohama, Japan
Study in Healthy Volunteers to Establish the BioEquivalence of Two Formulations of BG00012
- Conditions
- Healthy Volunteers
- First Posted Date
- 2011-08-19
- Last Posted Date
- 2011-11-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT01420458
- Locations
- 🇺🇸
Research Site, Minneapolis, Minnesota, United States
A Multiple-Dose, Open-Label, Phase 1, Pharmacokinetic, Pharmacodynamic, and Safety Study of Avonex® in Chinese Healthy Volunteer Subjects
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2011-11-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT01416207
- Locations
- 🇨🇳
Research Site, Shanghai, China
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Multiple SclerosisRelapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2016-01-14
- Lead Sponsor
- Biogen
- Target Recruit Count
- 97
- Registration Number
- NCT01416155
- Locations
- 🇯🇵
Research Site, Osaka, Japan
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
- Conditions
- Secondary Progressive Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 889
- Registration Number
- NCT01416181
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Phase 1 Study to Evaluate the PK, Safety, Tolerability of BIIB023 in Chinese, Japanese, and Caucasian Healthy Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- Drug: BIIB023 - low dose IV DoseDrug: BIIB023 - high dose IV Dose
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 48
- Registration Number
- NCT01407406
- Locations
- 🇨🇳
Research Site, Hong Kong, Hong Kong, China
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2015-08-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 290
- Registration Number
- NCT01405820
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
Persistence, Adherence, Quality of Life, and Treatment Satisfaction With Avonex® PEN™.
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 270
- Registration Number
- NCT01405872
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom